SHIELD THERAPEUTICS PLC
Commercializing a novel oral therapy for adults with iron deficiency.
STX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYV81293
- LEI:
- 213800G74QWY15FC3W71
- Country:
- United Kingdom
- Address:
- NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR, NE8 3DF GATESHEAD
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company focused on addressing the significant unmet medical need for patients with iron deficiency. The company's lead product is ACCRUFeR® (ferric maltol), a novel, stable, non-salt-based oral therapy for adults suffering from iron deficiency, with or without anemia. Shield Therapeutics is dedicated to the commercialization of its innovative treatments to improve the lives of patients across multiple therapeutic categories.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-14 16:01 |
Remuneration Information
Grant of Share Options to Chief Executive Officer
|
English | 26.5 KB | ||
| 2025-10-01 09:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 13.5 KB | ||
| 2025-10-01 08:02 |
Regulatory News Service
Positive efficacy and tolerance in pediatric trial
|
English | 18.7 KB | ||
| 2025-09-15 08:00 |
Share Issue/Capital Change
£1.5 million placing supporting growth of ACCRUFeR
|
English | 18.2 KB | ||
| 2025-08-27 08:13 |
Regulatory News Service
Data published -European Journal of Heart Failure
|
English | 21.9 KB | ||
| 2025-08-21 13:06 |
Earnings Release
Interim results for the six months ended 30 Jun 25
|
English | 245.5 KB | ||
| 2025-05-22 11:40 |
Annual Report
Shield Therapeutics plc 2024 Annual Report and Accounts
|
English | 4.4 MB | ||
| 2025-04-22 08:01 |
Business and Financial Review
Licence Agreement in Japan for ACCRUFeR®
|
English | 22.9 KB | ||
| 2025-03-11 08:00 |
Regulatory News Service
ACCRUFeR® launched in Canada
|
English | 21.0 KB | ||
| 2025-02-13 17:15 |
Director's Dealing
PDMR Transaction Notification
|
English | 28.6 KB | ||
| 2025-02-13 08:00 |
Remuneration Information
Grant of Share Options
|
English | 28.1 KB | ||
| 2025-02-05 08:00 |
Earnings Release
Unaudited full year trading update
|
English | 22.4 KB | ||
| 2025-01-27 08:00 |
Board/Management Information
Anders Lundstrom appointed CEO
|
English | 18.7 KB | ||
| 2024-12-24 12:25 |
Post-Annual General Meeting Information
Result of General Meeting & Total Voting Rights
|
English | 27.9 KB | ||
| 2024-12-23 08:00 |
Share Issue/Capital Change
Results of RetailBook Offer
|
English | 20.0 KB |
Automate Your Workflow. Get a real-time feed of all SHIELD THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SHIELD THERAPEUTICS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHIELD THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
